Entrectinib is a potent TRK, ROS1, and ALK kinase inhibitor that was tested in three phase I/II clinical trials of 54 cancer patients carrying NTRK fusions (age: 1 month–84 years) and showed an impressive ORR of 57% and good tolerability [137] (Figure 1). This evidence concerns the gene NTRK1 and cancer.